Driving patient health and independence

Patient health

We commit to placing patient health and independence at the heart of our operations, striving to continuously enhance the patient experience through intuitive, safe, and user-centric medical devices.

These efforts support the target to empower more than 8 million patients to live more independently by 2030.

Impacts

Putting patients' needs at the forefront of everything we do enables them to manage their health more independently, helping improve outcomes and supporting their overall wellbeing.

Addressing patients' practical, physical and emotional needs related to injections directly supports their independence and quality of life.

Key impact areas:

↘ Treatment adherence and persistency
↘ Health outcomes and quality of life
↘ Independence
↘ Accessibility

Approach

We employ a patient-centric design approach, integrating insights from usability experts, engineers, and patients themselves.

Technologies such as the Molly® Connected Cap autoinjector add-on and the Needle Isolation Technology (NIT®) are specifically developed to help improve patient adherence and overcome common barriers, such as needle fear.

Progress

In 2024, we continued to contribute to patient health by supporting pharmaceutical and biotech partners in launching combination products across a range of therapeutic areas.

From endocrine disorders to oncology, these collaborations enabled the development of self-administered solutions that help improve treatment adherence, promote patient independence, and enhance quality of life.

In 2024 alone, SHL Medical enabled 5.6 million patients to live more independently lives using SHL Medical devices, up from 4.1 million in 2023.

This growth is primarily driven by the rapid expansion of the cardiometabolic therapy area, particularly treatments related to obesity and cardiovascular diseases, where demand for autoinjectors has sharply increased.

Obesity, now affecting more than one billion people globally, has come to be regarded as the "single greatest threat to public health for this century", and has increasingly been recognized as a chronic condition requiring long-term pharmacological treatment.



Methodological note on patients reached KPI
Considering the significant contribution of cardiometabolic treatments to our overall growth, we have refined the methodology used to estimate the number of patients reached within a given year through our device used in the treatment of obesity. As a result, data for 2022 and 2023 have been recalculated using the updated methodology to ensure consistency and comparability across reporting years. The updated approach leverages real-world data and average treatment duration to provide a more accurate and representative estimate. This targeted recalibration achieves significantly greater consistency and precision in our patient impact reporting. See page 59 for further details.

Access to reliable, high-quality healthcare remains a global challenge – particularly for patients living with chronic or complex conditions.

Through our device platforms, SHL Medical contributes to addressing conditions such as:
↘ Atopic disorders
↘ Inflammatory bowel diseases
↘ Cardiovascular diseases
↘ Migraine
↘ Multiple sclerosis
↘ Rheumatoid arthritis
↘ Weight management
↘ Postmenopausal osteoporosis

Insights

12
Our devices are used across all 12 IQVIA-defined therapeutic areas covering 40+ indications.

What's next: roadmap

Areas	→	Actions
Scalability		Ensuring scalability to address diverse therapeutic needs, from prevalent conditions to rare diseases, through the development of sustainable devices and the expansion of regional manufacturing to reduce CO_2 emissions and enhance regional manufacturing capacities

Aligned with UN Global Compact Principle 1, we are committed to respecting and supporting internationally proclaimed human rights, including the right to health. Our approach aims to contribute to SDG 3 (Good Health and Well-being) by placing patient health and independence at the core of our operations.

Innovation

We commit to driving innovation through patient-centric drug delivery solutions.

Our focus is to continually develop novel, patient-centric solutions that facilitate self-administration, address emerging therapeutic advancements, and support sustainable healthcare practices.

Impacts

Innovative drug delivery systems directly impact patient health by supporting treatment adherence, facilitating home-based administration and enhancing the overall patient experience. The ability to enable home-based delivery of large-volume and high-viscosity biologics further expands access to personalized treatments, especially in chronic disease and oncology. Innovation also drives resource efficiency, reducing environmental footprint throughout production and distribution.

Key impact areas:

- ↘ User needs: support for self-administration and patient independence
- ↘ Adaptability to emerging therapeutic advancements
- ↘ Resource efficiency and product environmental footprint
- ↘ Digital health integration and innovation

Approach

Our structured approach to innovation integrates patient insights, sustainability objectives, and adaptive technological solutions.

Research and development activities continuously inform our product pipeline, addressing emerging healthcare demands.

We operate under a vertically integrated business model, with the majority of production processes managed in-house. This structure allows for greater control over quality, innovation, and resource efficiency, as SHL Medical designs and builds its own manufacturing and testing equipment. Vertical integration also facilitates alignment across the device development value chain, supporting operational consistency and process optimization.

Progress

Elexy™

We introduced our first electromechanical autoinjector, designed to accommodate both pre-filled syringes (1.0 mL and 2.25 mL) and cartridges (3.0 mL and 5.0 mL). Its versatility significantly accelerates combination product development timelines and allows for greater flexibility across varying injection profiles, responding effectively to diverse therapeutic dosing requirements.

Molly® Connected Cap

The Molly® Connected Cap is a compact, retrofittable connectivity solution designed for our Molly modular platform technology. In 2024, we advanced its capability to accurately record and transmit real-time data on patient device usage, facilitating improved monitoring and treatment adherence. This development underscores our continued focus on integrating digital health technologies within our existing product platforms.

Large-volume/high-viscosity drug delivery systems

Throughout 2024, development on our drug delivery systems continued, addressing large-volume and high-viscosity therapeutics. These platforms are designed to meet the growing demand for personalized medicine, with potential application in therapeutic areas such as oncology, thereby enabling effective home-based self-administration of complex therapies.

What's next: roadmap

Areas	→	Actions
Innovations in many forms		Continue expanding our innovation efforts with a strong focus on digital integration, patient-centric design, and sustainable manufacturing – ensuring that future product developments remain closely aligned with patient needs, environmental responsibility, and our strategic goal of empowering greater patient independence

SUSTAINABLE DEVELOPMENT GOALS

Our approach contributes to SDG 9 (Industry, Innovation and Infrastructure) by advancing patient-centric drug delivery solutions that enable self-administration, support therapeutic innovation, and promote more sustainable healthcare practices.

Product quality and safety

We commit to ensuring the highest standards of product quality and patient safety. Quality and safety are non-negotiable cornerstones of our operations.

Impacts

Robust quality management and safety standards protect patients from risks associated with product use, ensure reliability, and maintain trust among healthcare providers, regulators, and patients.

Key impact areas:

↘ Patient safety and wellbeing
↘ Regulatory compliance
↘ Trust and confidence among stakeholders

Policies and approach

ISO 13485

Our quality system is certified to ISO 13485, ensuring consistent control over medical device design, production, and distribution in line with regulatory requirements.

ISO 14971

Device risk management complies with ISO 14971, supporting the identification and control of potential risks throughout the medical device lifecycle.

FDA 21 CFR 820

We comply with FDA 21 CFR Part 820, which outlines quality system requirements for medical devices marketed in the US, focusing on product safety and effectiveness.

Progress

In the reporting period we continued to strengthen the integration of quality and safety across all stages of our operations – from product development to large-scale manufacturing. Using a risk-based approach, ensuring that all materials, components, and sub-assemblies were tested with state-of-the-art inspection methods to meet stringent international standards.

We also successfully completed the ISO 13485 certification audit at our testing lab in Switzerland, expanding the scope of our quality management system to formally include this location in addition to the existing coverage of drug delivery system design and development.

Our approach supports UN Global Compact Principle 1, by respecting the right to health and safety, and contributes to SDG 3 (Good Health and Well-being).